Clinical Trial

The Role of Brief Potent Glutamatergic Modulation in Addressing Problem Drinking

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated November 7, 2023 (before its estimated August 31, 2024 completion). Its status may not reflect the trial's current state.
Summary
The proposed project tests the efficacy of glutamate modulators in non-depressed individuals with alcohol use disorder (AUD); the primary hypothesis is that the glutamate modulator being tested reduces heavy drinking days compared to the active control. It also aims to investigate, using a 2 by 2 factorial (2x2) design, the hypothesis that the effects of the glutamate modulator are enhanced when combined with behavioral treatment.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2019-09-06; most recent amendment 2026-05-19.
Status change: Recruiting → Terminated 2026-04-16
Status change: Not Yet Recruiting → Recruiting 2019-11-22
Trial Details
NCT Number NCT04084860
Lead Sponsor New York State Psychiatric Institute
Collaborators: National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Conditions Alcohol Use Disorder
Enrollment 120 participants
Start Date 2019-11-08
Primary Completion 2024-08-31 (estimated)
Study Completion 2024-08-31 (estimated)
Updated on ClinicalTrials.gov 2023-11-07